Novo Nordisk’s Tresiba backed for use on NHS Wales
Novo Nordisk’s long-acting insulin Tresiba has been approved for routine use by NHS Wales as an option for treating diabetes.
Read More
Tag: long-acting insulin
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
